XML 17 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Cost of goods sold $ (188) $ (172) $ (434) $ (440)
Gross profit 278 208 705 623
Operating expenses:        
Research and development expenses 3,260 1,778 8,457 6,789
Selling, general and administrative expenses 1,998 4,002 6,571 9,204
Total operating expenses 5,258 5,780 15,028 15,993
Operating loss (4,980) (5,572) (14,323) (15,370)
Change in fair value of the warrant liability, net   434 (2,832) 451
Loss on issuance of financial instrument   1,714   1,721
Interest expense (44) (671) (154) (4,735)
Other income 33 4 182 4
Net loss (4,991) (7,519) (17,127) (21,371)
Deemed dividend for triggering of warrant down round feature     (55)  
Net loss attributable to common stockholders (4,991) (7,519) (17,182) (21,371)
Net loss (4,991) (7,519) (17,127) (21,371)
Other comprehensive (loss) income:        
Foreign currency translation adjustments (103) 89 (39) 39
Total other comprehensive loss $ (5,094) $ (7,430) $ (17,166) $ (21,332)
Common share data:        
Basic loss per common share [1] $ (1.16) $ (73.82) $ (7.75) $ (207.58)
Diluted loss per common share [1] $ (1.16) $ (73.82) $ (7.75) $ (207.58)
Weighted average number of basic shares outstanding [1] 4,288,593 101,862 2,217,611 102,956
Weighted average number of diluted shares outstanding [1] 4,288,593 101,862 2,217,611 102,956
Product Revenue [Member]        
Revenue $ 340 $ 216 $ 778 $ 528
Other Revenue [Member]        
Revenue $ 126 $ 164 $ 361 $ 535
[1] * reflects, one-for-seven hundred (1:700) reverse stock split effected on December 24, 2019.